MA-PERKINELMER
PerkinElmer , a global leader committed to innovating for a healthier world, today announced the addition of new assay kits to help further GPCR (G Protein-Coupled Receptor) therapeutic discovery . The new PerkinElmer offerings extend the company’s leading GPCR analysis portfolio, which includes innovative assays, plate readers, automation technologies and software solutions combined with siRNA, shRNA, CRISPR, and cDNA/ORFlibraries to help scientists more easily and accurately characterize receptors, screen compounds and streamline workflows.
The new assays, which enable researchers to use the preferred cell models of their choice, include the HTRF GTP Gi binding kit, the industry’s first TR-FRET based assay for GTP binding; the B-arr2 recruitment kit; and HTRF total kits for B-Arrestin 1, B-Arrestin 2 and AP2. These assays will help scientists continue to better understand the important role GPCRs play in disease by studying the interaction, expression and potential modulation of intracellular proteins involved in GPCR signaling mechanisms.
Further, when the new kits are leveraged as part of PerkinElmer’s comprehensive range of GPCR solutions, users can fully characterize the GPCRs being studied -- from ligand binding with the Tag-Lite® platform, and 2nd messenger with the cAMP and IP-One™ kits , to downstream GPCR signaling with hundreds of available assays. With the recent acquisition of Horizon Discovery, the PerkinElmer portfolio also includes siRNA, shRNA, CRISPR guide RNA, and cDNA/ORF libraries, such as ON-TARGETplus™, SMARTvector™ and Edit-R™ and screening services, which help researchers better explore the impact of gene modulation and editing on GPCR disease drivers.
“With GPCR-targeting drugs accounting for more than 30% of all FDA approved therapeutics and 20% of all drugs being studied, this area of research and development has been incredibly fruitful and holds immense potential for the future,” said Alan Fletcher, VP and GM of Life Sciences, PerkinElmer. “By adding these new assays to our already robust GPCR capabilities, we are giving researchers an end-to-end solution for continuing to unlock the role GPCRs play in disease so new and better therapeutics can be uncovered.”
For more information on the new kits and PerkinElmer’s extensive line up of GPCR offerings please visit: https://www.perkinelmer.com/category/gpcr-research-reagents and https://horizondiscovery.com/en/screening/screening-libraries .
About PerkinElmer
PerkinElmer enables scientists, researchers and clinicians to address their most critical challenges across science and healthcare. With a mission focused on innovating for a healthier world, we deliver unique solutions to serve the diagnostics, life sciences, food and applied markets. We strategically partner with customers to enable earlier and more accurate insights supported by deep market knowledge and technical expertise. Our dedicated team of about 14,000 employees worldwide is passionate about helping customers work to create healthier families, improve the quality of life, and sustain the wellbeing and longevity of people globally. The Company reported revenue of approximately $2.9 billion in 2019, serves customers in 190 countries, and is a component of the S&P 500 index. Additional information is available through 1-877-PKI-NYSE, or at www.perkinelmer.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210126006043/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Moody’s Agentic Solutions to Automate Complex Workflows and Speed Human Decision-Making16.9.2025 14:00:00 CEST | Press release
Moody’s today announced Agentic Solutions, a groundbreaking addition to its suite of AI-powered offerings designed to transform how organizations make decisions in complex, high-stakes environments. The new solutions empower organizations to act with greater speed, precision, and confidence than ever before, reshaping how risk is decoded, opportunities are identified, and decisions are made. “For over a century, our customers have looked to Moody’s for premium data, trusted insights, and cutting-edge solutions to help them make better, more informed decisions,” said Rob Fauber, President and CEO of Moody’s. “Agentic Solutions is a natural extension of our legacy of investment and innovation – anchored in the strength of our industry leading data-estate and the depth of our people’s analytical skills. By integrating agentic capabilities into the workflows of our customers, we are supercharging the speed and precision at which we can help our customers understand risk and unlock opportun
Takeda and VELA to Ship Medicines Across the Atlantic Using First-of-its-Kind Wind-Powered Trimaran16.9.2025 14:00:00 CEST | Press release
VELA to operate the world’s first sailing cargo trimaran powered by 100 percent wind when at sea1 to sail between Europe and the U.S.Takeda to become the first biopharmaceutical company to ship its products on VELA’s wind-powered trimaran, starting a new era of sustainable shipping in pharma Takeda (TSE:4502/NYSE:TAK) and VELA Transport today announced their business partnership, with Takeda set to become the first biopharmaceutical company to transport its products between Europe and the U.S. using VELA’s first-of-its-kind sailing cargo trimaran. VELA designed and will operate a fleet of new generation sailing cargo vessels, powered 100 percent by wind when at sea. Purpose-built to handle pharmaceutical products, VELA will offer reliable, secure and ultra-low-emission sea freight shipping. The maiden voyage is planned for late 2026. VELA’s new wind-powered sea freight will offer a climate-conscious alternative to other transportation for the pharmaceutical industry – cutting use-relat
Franklin Templeton Forms Strategic Partnership with Copenhagen Infrastructure Partners, DigitalBridge, and Actis to Expand Infrastructure Solutions for Private Wealth16.9.2025 14:00:00 CEST | Press release
Franklin Templeton, a global investment leader with more than $1.6 trillion in assets under management, together with three leading institutional infrastructure investment firms: Actis, the Sustainable Infrastructure business of General Atlantic; Copenhagen Infrastructure Partners (“CIP”); and DigitalBridge, today announced a strategic partnership to deliver private infrastructure solutions to individual investors. This partnership seeks to provide private wealth clients with differentiated access to high-growth infrastructure opportunities, thematically focused on energy security, electrification, and digitalization, as well as sectors including data centers and hyperscaler development, renewable energy, fiber and towers, and digital power. “We are excited to partner with three leading firms: DigitalBridge, CIP, and Actis, in response to a compelling market demand for allocations to infrastructure,” said Jenny Johnson, President and CEO, Franklin Templeton. “The trends shaping the pri
Matrix Executions Unveils White-Label Equity Options Algos: True Customization for Broker-Dealers16.9.2025 13:45:00 CEST | Press release
Matrix Executions, a leader in options trading technology, announced its latest launch of its white-label equity options algorithmic trading solutions. This product empowers broker dealers with true customization and control, enabling them to offer a bespoke algo trading experience to their clients. The product leverages Matrix Executions’ advanced execution algo suite overlayed with the Matrix QRX ATS for an all-in-one answer to execution customization. In today's dynamic market, a one-size-fits-all approach no longer works. Matrix Executions’ offering provides broker dealers with the ability to define, configure, and deploy option algorithms with varying levels of precision. This isn't just a re-skinned product but a foundation for dynamic innovation. The Matrix white-label solution provides extensive bespoke parameter configurations and true customization. Their robust strategy configuration library allows broker-dealers to fine-tune specific variables to optimize performance for di
Tecnotree Named a Visionary in the 2025 Gartner® Magic Quadrant™ for AI in CSP Customer and Business Operations16.9.2025 13:38:00 CEST | Press release
Tecnotree, a global leader in AI, 5G, and cloud-native digital platforms and services has been recognized as a Visionary in the 2025 Gartner® Magic Quadrant™ for AI in CSP Customer and Business Operations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250916788293/en/ Tecnotree Named a Visionary in the 2025 Gartner® Magic Quadrant™ for AI in CSP Customer and Business Operations We feel this underscores the company’s ability to deliver AI-powered, cloud-native platforms that enable communications service providers (CSPs) and enterprises worldwide to accelerate digital transformation, monetize networks, and deliver hyper-personalized customer experiences. The Gartner report, authored by analysts Pulkit Pandey, Amresh Nandan, Will Rice, and Mounish Rai, evaluates leading AI vendors for CSP customer and business operations. According to Gartner, AI in CSP customer and business operations helps CSPs utilize AI/ML to generate ins
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom